Precision Medicine CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Precision oncology based on whole‑genome and RNA sequencing is feasible and provides clinical benefit to a substantial proportion of patients with metastatic breast cancer.
The initial phase of this study demonstrates that precision oncology on the basis of whole‑genome and RNA sequencing is feasible when applied in the clinical management of patients with metastatic breast cancer and provides clinical benefit to a substantial proportion of patients.
This study shows that personalized treatment guided by comprehensive genomic techniques can improve outcomes for patients with metastatic breast cancer, underscoring the value of precision oncology in real‑world clinical practice.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC